[A23-143] Dostarlimab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 20.06.2024
Project no.:
A23-143
Commission:
Commission awarded on 21.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with mismatch repair deficient / microsatellite instability‑high primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy
- Patients with primary FIGO stage III: hint of lesser benefit
- Patients with primary FIGO stage IV or recurrent: indication of major added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-143_en
| Project no. | Title | Status |
|---|---|---|
| A21-84 | Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-59 | Dostarlimab (endometrial cancer) - Addendum to Project A23-143 | Commission completed |
Federal Joint Committee (G-BA)
2024-06-20 A G-BA decision was published.